Evidence map›Paper›PMID 33987233›Full record

ArticleAnnals of translational medicine2021

Oral care and oral assessment guide in breast cancer patients receiving everolimus and exemestane: subanalysis of a randomized controlled trial (Oral Care-BC).

Masahiro Umeda, Yoshihide Ota, Kosuke Kashiwabara, Naoki Hayashi, Mariko Naito, Toshinari Yamashita, Hirofumi Mukai, Katsuhiko Nakatsukasa, Takeshi Amemiya, Ken-Ichi Watanabe and 10 more

Open access · diamondAbstract read
In one paragraph

Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 11 institutions in 1 country.

Masahiro UmedaDepartment of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Yoshihide OtaDepartment of Oral and Maxillofacial Surgery, Tokai University School of Medicine, Tokyo, Japan.
Kosuke KashiwabaraData Science Office, Clinical Research Promotion Center, The University of Tokyo Hospital, Tokyo, Japan.
Naoki HayashiDepartment of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan.
Mariko NaitoDepartment of Oral Epidemiology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Toshinari YamashitaDepartment of Breast and Endocrine Surgery, Kanagawa Cancer Center, Kanagawa, Japan.
Hirofumi MukaiDepartment of Breast and Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
Katsuhiko NakatsukasaDepartment of Breast and Endocrine Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Takeshi AmemiyaDepartment of Dentistry and Oral and Maxillofacial Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Ken-Ichi WatanabeDepartment of Breast Surgery, Hokkaido Cancer Center, Hokkaido, Japan.
Hironobu HataDepartment of Dentistry and Oral Surgery, Hokkaido Cancer Center, Hokkaido, Japan.
Yuichiro KikawaDepartment of Breast Surgery, Kobe City Medical Center General Hospital, Kobe, Japan.
Naoki TaniikeDepartment of Dentistry and Oral and Maxillofacial Surgery, Kobe City Medical Center General Hospital, Kobe, Japan.
Takashi YamanakaDepartment of Breast and Endocrine Surgery, Kanagawa Cancer Center, Kanagawa, Japan.
Sachiyo MitsunagaDepartment of Dentistry and Oral and Maxillofacial Surgery, Kanagawa Cancer Center, Kanagawa, Japan.
Kazuhiko NakagamiDepartment of Breast and Endocrine Surgery, Shizuoka General Hospital, Shizuoka, Japan.
Moriyasu AdachiDepartment of Oral and Maxillofacial Surgery, Shizuoka General Hospital, Shizuoka, Japan.
Naoto KondoDepartment of Breast and Endocrine Surgery, Nagoya City University Hospital, Nagoya, Japan.
Yasuyuki ShibuyaDepartment of Oral and Maxillofacial Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Naoki NiikuraDepartment of Breast and Endocrine Surgery, Tokai University School of Medicine, Tokyo, Japan.
Nagasaki University · JPKanagawa Cancer CenterKyoto Prefectural University of Medicine · JPSt. Luke's International Hospital · JPTokai University · JPUniversity of Tokyo Hospital · JPHiroshima University · JPKanagawa Prefectural Hospital Organization · JPNagoya City University Hospital · JPNational Cancer Center Hospital East · JPShizuoka General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOral mucositis is a clinically significant adverse event linked to cancer therapy; it reduces the quality of life of patients and may result in the discontinuation of treatment and a poorer prognosis. Based on level 3 evidence, the Mucositis Study Group of Multinational Association for Supportive Care in Cancer and the International Society of Oral Oncology recommend oral care for all patients receiving cancer chemotherapy and radiotherapy, although no data from large-scaled randomized controlled trials support the efficacy of oral care in preventing oral mucositis. Therefore, this randomized, controlled, multicenter, open-label, phase III study sought to determine whether professional oral care reduces oral mucositis in everolimus and exemestane-treated estrogen receptor-positive metastatic breast cancer patients.

methodsAltogether, 169 patients were randomized into the professional oral care (n=82) and control (n=87) groups. The professional oral care group received oral health instruction, professional mechanical tooth and tongue cleaning, gargling with a benzethonium chloride mouthwash, and dexamethasone ointment when grade 1 mucositis manifested. The control group received oral health instruction and gargling. Eight weeks after the everolimus and exemestane administration, the oral status (Oral Assessment Guide criteria) and oral mucositis status (Common Terminology Criteria for Adverse Events functional and clinical examinations) were evaluated.

resultsThe incidence of oral mucositis of any grade and grade 2 severe mucositis was significantly lower in the professional oral care group, based on the Common Terminology Criteria for Adverse Events functional and clinical examinations. The total Oral Assessment Guide score, total Oral Assessment Guide grade, and Oral Assessment Guide score of teeth/dentures and mucous membranes were significantly different between the two groups. The Oral Assessment Guide grade for swallow, lip, teeth/dentures, mucous membrane, tongue, and saliva significantly correlated to oral mucositis severity.

conclusionsProfessional oral care may prevent oral mucositis and improve teeth/denture conditions in patients receiving everolimus and exemestane.

Indexed as

Benzethoniumbreast neoplasmdexamethasoneeverolimusexemestane

Identifiers

PMID33987233
PMCPMC8105828
OpenAlexW3122348642

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.